CN106794236B - A群链球菌疫苗 - Google Patents

A群链球菌疫苗 Download PDF

Info

Publication number
CN106794236B
CN106794236B CN201580027379.8A CN201580027379A CN106794236B CN 106794236 B CN106794236 B CN 106794236B CN 201580027379 A CN201580027379 A CN 201580027379A CN 106794236 B CN106794236 B CN 106794236B
Authority
CN
China
Prior art keywords
fragment
protein
seq
spycep
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580027379.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106794236A (zh
Inventor
玛妮莎·潘迪
迈克尔·巴茨洛夫
迈克尔·戈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901382A external-priority patent/AU2014901382A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of CN106794236A publication Critical patent/CN106794236A/zh
Application granted granted Critical
Publication of CN106794236B publication Critical patent/CN106794236B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580027379.8A 2014-04-15 2015-04-15 A群链球菌疫苗 Active CN106794236B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014901382 2014-04-15
AU2014901382A AU2014901382A0 (en) 2014-04-15 Group a streptococcal vaccine
AU2014903042A AU2014903042A0 (en) 2014-08-06 Group a streptococcal vaccine
AU2014903042 2014-08-06
AU2014904453 2014-11-05
AU2014904453A AU2014904453A0 (en) 2014-11-05 Group a streptococcal vaccine
PCT/AU2015/050174 WO2015157820A1 (en) 2014-04-15 2015-04-15 Group a streptococcus vaccine

Publications (2)

Publication Number Publication Date
CN106794236A CN106794236A (zh) 2017-05-31
CN106794236B true CN106794236B (zh) 2021-09-03

Family

ID=54323282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027379.8A Active CN106794236B (zh) 2014-04-15 2015-04-15 A群链球菌疫苗

Country Status (16)

Country Link
US (2) US10301362B2 (enExample)
EP (1) EP3131575B1 (enExample)
JP (2) JP2017513849A (enExample)
KR (2) KR102730367B1 (enExample)
CN (1) CN106794236B (enExample)
AU (1) AU2015246654B2 (enExample)
BR (1) BR112016023915B1 (enExample)
CA (1) CA2945052C (enExample)
DK (1) DK3131575T3 (enExample)
IL (1) IL248266B (enExample)
MX (1) MX392514B (enExample)
MY (1) MY191217A (enExample)
NZ (1) NZ725212A (enExample)
SG (1) SG11201608380PA (enExample)
WO (1) WO2015157820A1 (enExample)
ZA (1) ZA201607355B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015246654B2 (en) 2014-04-15 2019-08-08 Griffith University Group A streptococcus vaccine
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
SG11202001557PA (en) * 2017-08-23 2020-03-30 Univ Griffith Immunogenic peptide against group a streptococcus
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
KR102437436B1 (ko) * 2019-04-26 2022-08-30 주식회사 엠디헬스케어 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003515A1 (en) * 2006-07-07 2008-01-10 Intercell Ag Small streptococcus pyogenes antigens and their use
WO2009034473A2 (en) * 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2010076618A1 (en) * 2008-09-17 2010-07-08 Novartis Ag Combination gas vaccines and therapeutics

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
BRPI0610093A2 (pt) * 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
JP5102772B2 (ja) 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ：二量体化活性化治療剤
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
US8482298B2 (en) 2006-12-18 2013-07-09 Schrader Electronics Ltd. Liquid level and composition sensing systems and methods using EMF wave propagation
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides
AU2015246654B2 (en) 2014-04-15 2019-08-08 Griffith University Group A streptococcus vaccine
SG11202001557PA (en) * 2017-08-23 2020-03-30 Univ Griffith Immunogenic peptide against group a streptococcus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003515A1 (en) * 2006-07-07 2008-01-10 Intercell Ag Small streptococcus pyogenes antigens and their use
WO2009034473A2 (en) * 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2010076618A1 (en) * 2008-09-17 2010-07-08 Novartis Ag Combination gas vaccines and therapeutics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A Synthetic M Protein Peptide Synergizes with a CXC Chemokine Protease To Induce Vaccine-Mediated Protection against Virulent Streptococcal Pyoderma and Bacteremia";Manisha Pandey等;《J Immunol》;20150515;第194卷;第5915-5925页 *
"Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci";Manisha Pandey等;《J Immunol》;20160311;第196卷;第3364-3374页 *
"Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi";Claire E. Turner等;《Vaccine》;20090627;第27卷;第4926页右栏第5段，摘要 *
"Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T-cell help";Manisha Pandey等;《J Immunol》;20130315;第190卷(第6期);表1，摘要 *

Also Published As

Publication number Publication date
CN106794236A (zh) 2017-05-31
JP2021042247A (ja) 2021-03-18
CA2945052A1 (en) 2015-10-22
EP3131575A4 (en) 2017-11-01
MX392514B (es) 2025-03-24
DK3131575T3 (da) 2024-05-21
WO2015157820A1 (en) 2015-10-22
KR20160144455A (ko) 2016-12-16
AU2015246654B2 (en) 2019-08-08
KR102744193B1 (ko) 2024-12-19
US10513544B2 (en) 2019-12-24
MY191217A (en) 2022-06-09
CA2945052C (en) 2023-05-02
IL248266A0 (en) 2016-11-30
AU2015246654A1 (en) 2016-11-03
JP7072921B2 (ja) 2022-05-23
EP3131575B1 (en) 2024-05-08
ZA201607355B (en) 2019-03-27
NZ725212A (en) 2023-04-28
JP2017513849A (ja) 2017-06-01
IL248266B (en) 2021-09-30
MX2016013277A (es) 2017-01-18
KR20230039751A (ko) 2023-03-21
US20190256562A1 (en) 2019-08-22
US20170037087A1 (en) 2017-02-09
US10301362B2 (en) 2019-05-28
BR112016023915A2 (pt) 2017-10-17
EP3131575A1 (en) 2017-02-22
SG11201608380PA (en) 2016-11-29
BR112016023915B1 (pt) 2024-03-12
KR102730367B1 (ko) 2024-11-15

Similar Documents

Publication Publication Date Title
US10513544B2 (en) Group A streptococcus vaccine
US12383630B2 (en) Immunogenic peptide against group a Streptococcus
EP4081534B1 (en) Protective staphylococcal exotoxin vaccine
KR20210010882A (ko) 연쇄구균 독성 쇼크 증후군
HK1238144A1 (en) Group a streptococcus vaccine
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
HK1238144B (zh) A群链球菌疫苗
KR102893870B1 (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
WO2023227563A1 (en) Protective staphylococcal exotoxin vaccine
US20180243392A1 (en) Cs21 and lnga protein vaccines
EP4038087A2 (en) Non-toxic listeriolysin o polypeptides and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238144

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment